Companies Karyopharm Therapeutics
Karyopharm Therapeutics (KPTI): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Karyopharm Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,626,288FY2023
- $2,069,341FY2024
- $2,320,902FY2025
CEO total pay was $2,320,902 in fiscal 2025, up from $2,069,341 in fiscal 2024.
FY2025: salary $770,000 · bonus $100,100 · stock awards $838,996 · option awards $241,544
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Richard Paulson | $770,000 | $100,100 | $838,996 | $241,544 | $350,350 | $0 | $19,912 | $2,320,902 |
| President and Chief Executive Officer | ||||||||
| Reshma Rangwala | 567,736 | 1,051,096 | 79,492 | 120,766 | 178,837 | 0 | 18,207 | 2,016,134 |
| Executive Vice President, Chief Medical Officer and Head of Research | ||||||||
| Stuart Poulton | 500,135 | 295,012 | 312,293 | 115,736 | 157,543 | 0 | 18,861 | 1,399,580 |
| Executive Vice President, Chief Development Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Richard Paulson | $2,320,902 | $2,069,341 | $2,626,288 | ↑ +251,561 |
| Reshma Rangwala | 2,016,134 | 1,124,444 | 1,227,789 | ↑ +891,690 |
| Stuart Poulton | 1,399,580 | — | 1,109,115 | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract and retain top talent, reward strong performance, and align incentives with the creation of long-term stockholder value, while also considering the Company’s cash and equity resource constraints.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine, WTW |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Stuart Poulton | Option | 181 | 154.95 | — |
| Stuart Poulton | RSU | 416 | — | 3,062 |
| Stuart Poulton | Option | 438 | 69.15 | — |
| Reshma Rangwala | Option | 556 | 91.5 | — |
| Stuart Poulton | RSU | 750 | — | 5,520 |
| Richard Paulson | Option | 999 | 154.95 | — |
| Reshma Rangwala | RSU | 1,083 | — | 7,971 |
| Stuart Poulton | PSU | 1,779 | — | 13,093 |
| Reshma Rangwala | PSU | 1,889 | — | 13,903 |
| Stuart Poulton | RSU | 2,111 | — | 15,537 |
| Reshma Rangwala | RSU | 2,222 | — | 16,354 |
| Stuart Poulton | PSU | 2,688 | — | 19,784 |
| Reshma Rangwala | PSU | 2,842 | — | 20,917 |
| Stuart Poulton | RSU | 4,583 | — | 33,731 |
| Reshma Rangwala | RSU | 4,583 | — | 33,731 |
| Richard Paulson | RSU | 4,812 | — | 35,416 |
| Stuart Poulton | RSU | 5,000 | — | 36,800 |
| Reshma Rangwala | RSU | 5,416 | — | 39,862 |
| Richard Paulson | RSU | 5,600 | — | 41,216 |
| Richard Paulson | PSU | 5,600 | — | 41,216 |
| Stuart Poulton | RSU | 8,364 | — | 61,559 |
| Reshma Rangwala | RSU | 8,842 | — | 65,077 |
| Stuart Poulton | Option | 9,166 | 7.95 | — |
| Reshma Rangwala | Option | 9,166 | 7.95 | — |
| Stuart Poulton | Option | 10,000 | 7.95 | — |
| Reshma Rangwala | Option | 10,833 | 7.95 | — |
| Richard Paulson | PSU | 14,760 | — | 108,634 |
| Richard Paulson | RSU | 19,680 | — | 144,845 |
| Richard Paulson | RSU | 20,000 | — | 147,200 |
| Stuart Poulton | RSU | 39,682 | — | 292,060 |
| Richard Paulson | Option | 40,000 | 7.95 | — |
| Richard Paulson | RSU | 114,285 | — | 841,138 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Barry E. GreeneIndependent · Lead Independent Director · Compensation Committee · Nominating, Corporate Governance Compliance Committee (Chair) | $115,000 | $0 | $15,142 | — | $0 | $130,142 |
| Mansoor Raza Mirza, M.DIndependent · Commercialization and Portfolio | 41,413 | 0 | 15,142 | — | 60,000 | 116,555 |
| Deepika R. Pakianathan, Ph.DIndependent | 90,000 | 0 | 15,142 | — | 0 | 105,142 |
| Garen G. BohlinIndependent · Audit Committee (Chair) · Nominating, Corporate Governance Compliance Committee | 80,000 | 0 | 15,142 | — | 0 | 95,142 |
| Christy J. OligerIndependent · Compensation Committee · Commercialization and Portfolio Committee (Chair) | 80,000 | 0 | 15,142 | — | 0 | 95,142 |
| Chen Schor, M.B.A., C.P.AIndependent | 70,000 | 0 | 15,142 | — | 0 | 85,142 |
| Zhen Su, M.D., M.B.AIndependent · Commercialization and Portfolio | 60,000 | 0 | 15,142 | — | 0 | 75,142 |
| Richard Paulson, M.B.AEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $15,142 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 20,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $536,413 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $60,000 |
| Total cost of the board | $596,413 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Karyopharm Therapeutics as a peer
Companies that benchmark against KPTI
17 companies name KPTI as a compensation peer
The list of companies that name KPTI as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Karyopharm Therapeutics | 2025 | Richard Paulson | $770,000 | $838,996 | $241,544 | $350,350 | $2,320,902 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 10,025,198 | 1,388,274 | 17,213 | 87.84% | Passed |
| 2025 | 2025-05-28 | 2,716,951 | 1,041,611 | 296,611 | 72.29% | Passed |
| 2024 | 2024-05-29 | 55,719,917 | 12,055,044 | 65,930 | 82.21% | Passed |
| 2023 | 2023-05-24 | 64,822,475 | 17,787,485 | 275,738 | 78.47% | Passed |
| 2022 | 2022-05-19 | 47,288,439 | 6,790,078 | 230,065 | 87.44% | Passed |
| 2021 | 2021-05-21 | 37,981,962 | 2,969,679 | 122,936 | 92.75% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-21 | 87.84%a |
| 2025 | 2025-05-28 | 72.29%b |
| 2024 | 2024-05-29 | 82.21%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Reshma Rangwala | EVP & Chief Medical Officer | 2026-04-21 | D | 449 | $9 | $4,014 | Common | Form 4 ↗ |
| Kristin Abate | Chief Accounting Officer | 2026-05-13 | A | 121 | 0 | 0 | Common | Form 4 ↗ |
| Michael Mano | EVP, CLO&Secretary | 2026-05-13 | A | 700 | 0 | 0 | Common | Form 4 ↗ |
| Richard Paulson | Director | 2026-05-13 | A | 4,920 | 0 | 0 | Common | Form 4 ↗ |
| Sohanya Roshan Cheng | EVP & Chief Commercial Officer | 2026-05-13 | A | 947 | 0 | 0 | Common | Form 4 ↗ |
| Reshma Rangwala | EVP & Chief Medical Officer | 2026-05-13 | A | 947 | 0 | 0 | Common | Form 4 ↗ |
| Stuart Poulton | EVP, Chief Development Officer | 2026-05-13 | A | 896 | 0 | 0 | Common | Form 4 ↗ |
| Michael Mano | EVP, CLO&Secretary | 2026-05-14 | D | 266 | 10 | 2,527 | Common | Form 4 ↗ |
| Sohanya Roshan Cheng | EVP & Chief Commercial Officer | 2026-05-14 | D | 324 | 10 | 3,078 | Common | Form 4 ↗ |
| Reshma Rangwala | EVP & Chief Medical Officer | 2026-05-14 | D | 408 | 10 | 3,876 | Common | Form 4 ↗ |
| Stuart Poulton | EVP, Chief Development Officer | 2026-05-14 | D | 403 | 10 | 3,829 | Common | Form 4 ↗ |
| Richard Paulson | Director | 2026-05-14 | D | 2,203 | 10 | 20,929 | Common | Form 4 ↗ |
| Kristin Abate | Chief Accounting Officer | 2026-05-14 | D | 53 | 10 | 504 | Common | Form 4 ↗ |
| Barry E. Greene | Director | 2026-05-21 | A | 15,508 | 0 | 0 | Common | Form 4 ↗ |
| Garen G. Bohlin | Director | 2026-05-21 | A | 15,508 | 0 | 0 | Common | Form 4 ↗ |
| Zhen Su | Director | 2026-05-21 | A | 15,508 | 0 | 0 | Common | Form 4 ↗ |
| Deepika Pakianathan | Director | 2026-05-21 | A | 15,508 | 0 | 0 | Common | Form 4 ↗ |
| Chen Schor | Director | 2026-05-21 | A | 15,508 | 0 | 0 | Common | Form 4 ↗ |
| Christy J. Oliger | Director | 2026-05-21 | A | 15,508 | 0 | 0 | Common | Form 4 ↗ |
| Stuart Poulton | EVP, Chief Development Officer | 2026-07-28 | D | 189 | 7 | 1,342 | Common | Form 4 ↗ |
| Kristin Abate | Chief Accounting Officer | 2026-09-01 | D | 19 | 2 | 38 | Common | Form 4 ↗ |
| Kristin Abate | Chief Accounting Officer | 2026-10-01 | D | 378 | 1 | 450 | Common | Form 4 ↗ |
| Kristin Abate | Chief Accounting Officer | 2026-10-16 | D | 4,788 | 0 | 1,647 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (41 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Richard Paulson. DEF 14A, filed 2026-04-13. Section “025 Summary Compensation Table” · page 61. As printed: 2,320,902. View filing ↗
- Section 01, Reshma Rangwala. DEF 14A, filed 2026-04-13. Section “025 Summary Compensation Table” · page 61. As printed: 2,016,134. View filing ↗
- Section 01, Stuart Poulton. DEF 14A, filed 2026-04-13. Section “025 Summary Compensation Table” · page 61. As printed: 1,399,580. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-02-13. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Barry E. Greene. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 130,142. View filing ↗
- Section 08, Mansoor Raza Mirza, M.D. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 116,555. View filing ↗
- Section 08, Deepika R. Pakianathan, Ph.D. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 105,142. View filing ↗
- Section 08, Garen G. Bohlin. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 95,142. View filing ↗
- Section 08, Christy J. Oliger. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 95,142. View filing ↗
- Section 08, Chen Schor, M.B.A., C.P.A. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 85,142. View filing ↗
- Section 08, Zhen Su, M.D., M.B.A. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 75,142. View filing ↗
- Section 08, Richard Paulson, M.B.A. DEF 14A, filed 2026-04-13. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Reshma Rangwala 2026-04-21. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Abate 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Mano 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Paulson 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sohanya Roshan Cheng 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Reshma Rangwala 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stuart Poulton 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Mano 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sohanya Roshan Cheng 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Reshma Rangwala 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stuart Poulton 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Paulson 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Abate 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry E. Greene 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garen G. Bohlin 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Zhen Su 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deepika Pakianathan 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chen Schor 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christy J. Oliger 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stuart Poulton 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Abate 2026-09-01. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Abate 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Abate 2026-10-16. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-28. Item 5.07 · say-on-pay result. As reported: 87.84% (votes for as printed: 10,025,198). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-29. Item 5.07 · say-on-pay result. As reported: 72.29% (votes for as printed: 2,716,951). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-31. Item 5.07 · say-on-pay result. As reported: 82.21% (votes for as printed: 55,719,917). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 536,413 + equity 0 + all other 60,000 = 596,413, summed across the director compensation table rows.
- Karyopharm Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. View filing ↗